An unusual cause of growth failure in cystic fibrosis: A salutary reminder of the interaction between glucocorticoids and cytochrome P450 inhibiting medication
Authors:
- 1 July 2015
- journal article
- case report
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 14 (4) , e9-e11
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATIONDrug Metabolism and Disposition, 2006
- ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITIONDrug Metabolism and Disposition, 2004
- Survey of adrenal crisis associated with inhaled corticosteroids in the United KingdomArchives of Disease in Childhood, 2002
- Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulationsBritish Journal of Clinical Pharmacology, 2001
- Systemic Adverse Effects of Inhaled Corticosteroid TherapyArchives of internal medicine (1960), 1999
- Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjectsBritish Journal of Clinical Pharmacology, 1997
- Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionateThe Lancet, 1996
- Pharmacodynamics and pharmacokinetics of inhaled glucocorticoidsJournal of Allergy and Clinical Immunology, 1996
- The human pharmacology of fluticasone propionateRespiratory Medicine, 1990
- Nasal bioavailability and systemic effects of the glucocorticoid budesonide in manEuropean Journal of Clinical Pharmacology, 1985